| |||||||
| |||||||
1 | SENATE RESOLUTION | ||||||
2 | WHEREAS, Serious mental illnesses like bipolar disorder, | ||||||
3 | major depressive disorder, and schizophrenia often require | ||||||
4 | treatment with antipsychotic medications for effective | ||||||
5 | management, and antipsychotic prescribing rates continue to | ||||||
6 | rise; and | ||||||
7 | WHEREAS, While prolonged antipsychotic use may be | ||||||
8 | essential for the treatment of certain conditions, it is | ||||||
9 | associated with tardive dyskinesia (TD), a condition marked by | ||||||
10 | uncontrollable, abnormal, and repetitive movements of the | ||||||
11 | face, torso, limbs, or extremities; and | ||||||
12 | WHEREAS, People at higher risk of TD include those older | ||||||
13 | than 55 years, people who are Black, women, individuals with | ||||||
14 | mood or substance use disorders, intellectual disabilities, or | ||||||
15 | central nervous system injuries, and those with high | ||||||
16 | cumulative antipsychotic exposure; and | ||||||
17 | WHEREAS, Approximately 60% of the estimated 800,000 U.S. | ||||||
18 | adults living with TD remain undiagnosed, and even mild TD | ||||||
19 | symptoms can be stigmatizing and impair physical, social, and | ||||||
20 | emotional well-being, underscoring the urgency of early | ||||||
21 | screening, detection, and intervention; and |
| |||||||
| |||||||
1 | WHEREAS, The American Psychiatric Association recommends | ||||||
2 | routine TD screening in their clinical guidelines for | ||||||
3 | antipsychotic treatment, and individuals treated with | ||||||
4 | antipsychotics or experiencing abnormal movements should | ||||||
5 | consult their health care providers to assess TD risk, receive | ||||||
6 | TD screenings, and determine appropriate treatment together; | ||||||
7 | and | ||||||
8 | WHEREAS, FDA-approved treatments for TD can provide | ||||||
9 | options for symptom management and improved quality of life | ||||||
10 | for many individuals living with TD; and | ||||||
11 | WHEREAS, The General Assembly can encourage TD screening | ||||||
12 | education and awareness for health care providers, patients, | ||||||
13 | and care partners to help ensure patients prescribed | ||||||
14 | antipsychotics receive care and support that aligns with | ||||||
15 | clinical best practices, including regular TD screenings; | ||||||
16 | therefore, be it | ||||||
17 | RESOLVED, BY THE SENATE OF THE ONE HUNDRED FOURTH GENERAL | ||||||
18 | ASSEMBLY OF THE STATE OF ILLINOIS, that we declare May 4 | ||||||
19 | through May 10, 2025 as Tardive Dyskinesia Awareness Week | ||||||
20 | (TDAW) in the State of Illinois; and be it further | ||||||
21 | RESOLVED, That we support TDAW in recognition of the | ||||||
22 | importance of early detection and intervention to improve |
| |||||||
| |||||||
1 | outcomes for people living with mental health conditions and | ||||||
2 | prescribed antipsychotics, and we support efforts to raise | ||||||
3 | awareness about the causes and symptoms of tardive dyskinesia | ||||||
4 | (TD) and the importance of routine TD screening. |